Josh Jennings
Stock Analyst at Morgan Stanley
(2.55)
# 2,217
Out of 5,116 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $22.01 | +140.80% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $288.82 | +3.87% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $3.95 | +406.33% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $18.89 | +233.51% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.70 | +903.58% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $86.29 | -53.64% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $22.01
Upside: +140.80%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $288.82
Upside: +3.87%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $3.95
Upside: +406.33%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $18.89
Upside: +233.51%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.70
Upside: +903.58%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $86.29
Upside: -53.64%